<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115308</url>
  </required_header>
  <id_info>
    <org_study_id>Astellas CMR Tagging</org_study_id>
    <nct_id>NCT02115308</nct_id>
  </id_info>
  <brief_title>Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging</brief_title>
  <official_title>Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy M. Bateman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint Luke's Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Luke's Cardiovascular Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aspire Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the changes in cardiac function during a Lexiscan
      pharmacologic stress test using cardiac magnetic resonance imaging test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2014</start_date>
  <completion_date type="Actual">March 23, 2018</completion_date>
  <primary_completion_date type="Actual">January 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RADIAL STRAIN</measure>
    <time_frame>Day 1</time_frame>
    <description>A measurement of the relative displacement between myocardial points between end-diastole and end-systole along a common ray extending from the center of the left ventricular (LV) cavity (analogous to myocardial thickening). A normal radial strain is indicated by a positive decimal value and can be understood as the percentage change in wall thickness of a myocardial segment. A POSITIVE change in radial strain indicates an increase in wall thickening.
Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CIRCUMFERENTIAL STRAIN</measure>
    <time_frame>Day 1</time_frame>
    <description>A measurement of the relative displacement of myocardial points directed along the circumference of the ventricular wall at a given radial distance from the left ventricular (LV) cavity center (e.g. midline). A normal circumferential strain is indicated by a negative decimal value and can be understood as the percentage shortening along the ventricular wall with a greater negative value indicating greater ventricular shortening along the circumference. A positive change in strain would therefore be interpreted as a decrease in circumferential shortening.
Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Gadolinium Enhancement (LGE) and RADIAL Myocardial Strain</measure>
    <time_frame>Day 1</time_frame>
    <description>For each subject, the 16-segments were visually assessed along the short-axis plane for the presence of LGE. These images were collected post regadenoson stress recovery using an inversion-recovery prepared, fast gradient echo sequence and a delay of at least 8 minutes after administration of a single dose of gadobenate dimeglumine.
The presence of LGE within a segment is a separate classification of segment type. The segment classifications in the other outcomes are determined from the prior positron-emission-tomography (PET) examination where the LGE determination is based solely on cardiac magnetic resonance (CMR) imaging collected data.
The measurement was performed to determine if the presence of LGE within a particular segment affect the resulting strain?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1</time_frame>
    <description>Adverse events were monitored and recorded on a specific Adverse Event (AE) log.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Gadolinium Enhancement and CIRCUMFERENTIAL Myocardial Strain</measure>
    <time_frame>Day 1</time_frame>
    <description>The Effects of the presence of LGE on CIRCUMFERENTIAL myocardial Strain</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Regadenoson</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.</description>
    <arm_group_label>Regadenoson</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myocardial rest/regadenoson stress perfusion PET study within 60 days

          -  Normal rest LVEF (greater than or equal to 50%)

          -  No change in symptoms or treatment between the PET and the MRI study

          -  Willing to consent to the study

          -  Male or female who is either post-menopausal, surgically sterile, or if has a
             childbearing potential, a negative pregnancy test within 2 days prior to the MRI
             study.

        Exclusion Criteria:

          -  Renal dysfunction (estimated glomerular filtration rate &lt; 60 mL/min/1.73m2) within 6
             months

          -  Metallic implants, pacemaker, blood vessel clip (contra-indicated for MRI)

          -  Patient size exceeds MRI bore/table limits: (Max body diameter &gt; 60 cm, weight &gt; 136
             kg)

          -  History of gadolinium contrast allergy or intolerance

          -  Second or third degree AV block

          -  Sinus node dysfunction

          -  Acute myocardial infarction (past 3 months)

          -  Actively wheezing or with acute asthma or bronchospastic attacks requiring changes in
             therapy within the past 30 days

          -  Patients that have experienced a previous hypersensitivity reaction thought to be
             related to regadenoson
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aspire Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Luke's Health System</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2018</results_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aspire Foundation</investigator_affiliation>
    <investigator_full_name>Timothy M. Bateman</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02115308/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects were recruited from two groups: a population with coronary artery disease (CAD) of those with low-likelihood-CAD (Control). The myocardial segment perfusion and wall motion scores from the prior clinical positron-emission-tomography (PET) were used to classify segments as one of the following: CONTROL, CAD_REMOTE, CAD_REVERSIBLE.</recruitment_details>
      <pre_assignment_details>Cardiac Magnetic Resonance (CMR) imaging was performed in the same order for all subjects with rest imaging preceding regadenoson stress imaging.
The same prescription for tagged CMR slice locations (basal, mid, and apical) were used at both rest and stress.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CONTROL</title>
          <description>Myocardial strain imaging was performed for all subjects in a similar order. Rest-tag imaging was performed first, then Stress-tag imaging was performed at maximal heart rate following administration of the regadenoson dose.
Strain values were then calculated for each of 16-segments for each subject. Segments are classified based on myocardial perfusion imaging scores.
A Control subject is an individual from a population of low-likelihood CAD exhibiting both normal perfusion score and normal wall motion score rest-to-stress as indicated on a clinically indicated PET.</description>
        </group>
        <group group_id="P2">
          <title>Coronary Artery Disease</title>
          <description>Myocardial strain imaging was performed for all subjects in a similar order. Rest-tag imaging was performed first, then Stress-tag imaging was performed at maximal heart rate following administration of the regadenoson dose.
Strain values were then calculated for each of 16-segments for each subject. Segments are classified based on myocardial perfusion imaging scores.
A Coronary Artery Disease (CAD) subject is an individual from a population with CAD exhibiting both normal perfusion and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">Number of subjects recruited for the CONTROL group.</participants>
                <participants group_id="P2" count="25">Number of subjects recruited for the CAD group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13">Number of subjects recruited to the Control group meeting all inclusion criteria.</participants>
                <participants group_id="P2" count="23">Number of subjects recruited to the CAD group meeting all inclusion criteria.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Safety Screening</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CONTROL</title>
          <description>Myocardial strain imaging was performed for all subjects in a similar order. Rest-tag imaging was performed first, then Stress-tag imaging was performed at maximal heart rate following administration of the regadenoson dose.
Strain values were then calculated for each of 16-segments for each subject. Segments are classified based on myocardial perfusion imaging scores.
A control subject is an individual from a low-likelihood CAD population with a prior clinically indicated PET with perfusion and wall motion scores (rest-to-stress).</description>
        </group>
        <group group_id="B2">
          <title>Coronary Artery Disease</title>
          <description>Myocardial strain imaging was performed for all subjects in a similar order. Rest-tag imaging was performed first, then Stress-tag imaging was performed at maximal heart rate following administration of the regadenoson dose.
Strain values were then calculated for each of 16-segments for each subject. Segments are classified based on myocardial perfusion imaging scores.
A Coronary artery disease subject is an individual from a CAD population with a prior clinically indicated PET with perfusion and wall motion scores (rest-to-stress).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="10"/>
                    <measurement group_id="B2" value="72" spread="9"/>
                    <measurement group_id="B3" value="66" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="6"/>
                    <measurement group_id="B2" value="31" spread="6"/>
                    <measurement group_id="B3" value="31" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>RADIAL STRAIN</title>
        <description>A measurement of the relative displacement between myocardial points between end-diastole and end-systole along a common ray extending from the center of the left ventricular (LV) cavity (analogous to myocardial thickening). A normal radial strain is indicated by a positive decimal value and can be understood as the percentage change in wall thickness of a myocardial segment. A POSITIVE change in radial strain indicates an increase in wall thickening.
Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless.</description>
        <time_frame>Day 1</time_frame>
        <population>Myocardial segments classified according to subject groups and myocardial perfusion and wall motion scores on prior positron-emission-tomography (PET).</population>
        <group_list>
          <group group_id="O1">
            <title>CONTROL</title>
            <description>A myocardial segment from an individual from a low-likelihood coronary-artery-disease (CAD) population exhibiting both normal perfusion and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O2">
            <title>CAD_REMOTE</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting normal perfusion scores and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O3">
            <title>CAD_REVERSIBLE</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting a change in perfusion scores and a change in wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
        </group_list>
        <measure>
          <title>RADIAL STRAIN</title>
          <description>A measurement of the relative displacement between myocardial points between end-diastole and end-systole along a common ray extending from the center of the left ventricular (LV) cavity (analogous to myocardial thickening). A normal radial strain is indicated by a positive decimal value and can be understood as the percentage change in wall thickness of a myocardial segment. A POSITIVE change in radial strain indicates an increase in wall thickening.
Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless.</description>
          <population>Myocardial segments classified according to subject groups and myocardial perfusion and wall motion scores on prior positron-emission-tomography (PET).</population>
          <units>unitless (strain)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>myocardial segments</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>myocardial segments</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" spread="0.100"/>
                    <measurement group_id="O2" value="0.149" spread="0.098"/>
                    <measurement group_id="O3" value="0.150" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REGADENOSON STRESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.190" spread="0.113"/>
                    <measurement group_id="O2" value="0.167" spread="0.104"/>
                    <measurement group_id="O3" value="0.141" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REST-to-STRESS CHANGE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.137"/>
                    <measurement group_id="O2" value="0.022" spread="0.107"/>
                    <measurement group_id="O3" value="-0.009" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>REST-TO-REGADENOSON STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>paired, t-test</method>
            <method_desc>non-adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST-TO-REGADENOSON STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>non-adjusted</p_value_desc>
            <method>paired, t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-TO-REGADENOSON STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.495</p_value>
            <p_value_desc>non-adjusted</p_value_desc>
            <method>paired, t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.365</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non-adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.915</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.087</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST-TO-STRESS CHANGE</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.399</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-TO-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-TO-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CIRCUMFERENTIAL STRAIN</title>
        <description>A measurement of the relative displacement of myocardial points directed along the circumference of the ventricular wall at a given radial distance from the left ventricular (LV) cavity center (e.g. midline). A normal circumferential strain is indicated by a negative decimal value and can be understood as the percentage shortening along the ventricular wall with a greater negative value indicating greater ventricular shortening along the circumference. A positive change in strain would therefore be interpreted as a decrease in circumferential shortening.
Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless.</description>
        <time_frame>Day 1</time_frame>
        <population>Myocardial segments from the population groups according to the AHA 16-segment model and classified according to PET perfusion and wall motion scores.</population>
        <group_list>
          <group group_id="O1">
            <title>CONTROL</title>
            <description>A myocardial segment from an individual from a low-likelihood CAD population exhibiting both normal perfusion and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O2">
            <title>CAD_REMOTE</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting normal perfusion scores and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O3">
            <title>CAD_REVERSIBLE</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting a change in perfusion scores and a change in wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
        </group_list>
        <measure>
          <title>CIRCUMFERENTIAL STRAIN</title>
          <description>A measurement of the relative displacement of myocardial points directed along the circumference of the ventricular wall at a given radial distance from the left ventricular (LV) cavity center (e.g. midline). A normal circumferential strain is indicated by a negative decimal value and can be understood as the percentage shortening along the ventricular wall with a greater negative value indicating greater ventricular shortening along the circumference. A positive change in strain would therefore be interpreted as a decrease in circumferential shortening.
Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless.</description>
          <population>Myocardial segments from the population groups according to the AHA 16-segment model and classified according to PET perfusion and wall motion scores.</population>
          <units>strain (unitless)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>myocardial segments</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>myocardial segments</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.181" spread="0.056"/>
                    <measurement group_id="O2" value="-0.140" spread="0.057"/>
                    <measurement group_id="O3" value="-0.121" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REGADENSOSON STRESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.169" spread="0.059"/>
                    <measurement group_id="O2" value="-0.150" spread="0.053"/>
                    <measurement group_id="O3" value="-0.126" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REST-to-STRESS CHANGE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.065"/>
                    <measurement group_id="O2" value="-0.013" spread="0.051"/>
                    <measurement group_id="O3" value="-0.006" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Rest VS Regadenoson Stress</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>Non-adjusted.</p_value_desc>
            <method>paired, t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rest VS Regadenoson Stress</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>non-adjusted</p_value_desc>
            <method>paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Rest VS Regadenoson Stress</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>non-adjusted</non_inferiority_desc>
            <p_value>0.390</p_value>
            <method>paired, t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>non-adjusted</non_inferiority_desc>
            <p_value>&lt;0.000</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>non-adjusted</non_inferiority_desc>
            <p_value>&lt;0.000</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>non-adjusted</non_inferiority_desc>
            <p_value>0.022</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>non-adjusted</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.000</p_value>
            <p_value_desc>non-adjusted</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>non-adjusted</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST-TO-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.000</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non-adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-TO-STRESS Changes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non-adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-TO-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.310</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non-adjusted</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Gadolinium Enhancement (LGE) and RADIAL Myocardial Strain</title>
        <description>For each subject, the 16-segments were visually assessed along the short-axis plane for the presence of LGE. These images were collected post regadenoson stress recovery using an inversion-recovery prepared, fast gradient echo sequence and a delay of at least 8 minutes after administration of a single dose of gadobenate dimeglumine.
The presence of LGE within a segment is a separate classification of segment type. The segment classifications in the other outcomes are determined from the prior positron-emission-tomography (PET) examination where the LGE determination is based solely on cardiac magnetic resonance (CMR) imaging collected data.
The measurement was performed to determine if the presence of LGE within a particular segment affect the resulting strain?</description>
        <time_frame>Day 1</time_frame>
        <population>LGE imaging by CMR was acquired only in subjects meeting GFR restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>CONTROL</title>
            <description>A myocardial segment from an individual from a low-likelihood coronary-artery-disease (CAD) population exhibiting both normal perfusion and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O2">
            <title>LGE-</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting normal perfusion scores and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O3">
            <title>LGE+</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting a change in perfusion scores and a change in wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
        </group_list>
        <measure>
          <title>Late Gadolinium Enhancement (LGE) and RADIAL Myocardial Strain</title>
          <description>For each subject, the 16-segments were visually assessed along the short-axis plane for the presence of LGE. These images were collected post regadenoson stress recovery using an inversion-recovery prepared, fast gradient echo sequence and a delay of at least 8 minutes after administration of a single dose of gadobenate dimeglumine.
The presence of LGE within a segment is a separate classification of segment type. The segment classifications in the other outcomes are determined from the prior positron-emission-tomography (PET) examination where the LGE determination is based solely on cardiac magnetic resonance (CMR) imaging collected data.
The measurement was performed to determine if the presence of LGE within a particular segment affect the resulting strain?</description>
          <population>LGE imaging by CMR was acquired only in subjects meeting GFR restrictions.</population>
          <units>strain (unitless)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Myocardial Segments</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Myocardial Segments</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157" spread="0.100"/>
                    <measurement group_id="O2" value="0.155" spread="0.097"/>
                    <measurement group_id="O3" value="0.140" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REGADENOSON STRESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.190" spread="0.113"/>
                    <measurement group_id="O2" value="0.185" spread="0.107"/>
                    <measurement group_id="O3" value="0.132" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REST-to_STRESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" spread="0.136"/>
                    <measurement group_id="O2" value="0.031" spread="0.116"/>
                    <measurement group_id="O3" value="-0.008" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>REST vs STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>paired, t-test</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST vs STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>paired, t-test</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST vs STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.721</p_value>
            <method>paired, t-test</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.797</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.474</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.537</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.717</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST-to-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.908</p_value>
            <p_value_desc>non adjusted</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-to-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.187</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse events were monitored and recorded on a specific Adverse Event (AE) log.</description>
        <time_frame>Day 1</time_frame>
        <population>Count of Adverse Events not clinically expect and reportable to IRB.</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson</title>
            <description>Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
Regadenoson: Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
All subjects received a dose of Regadenoson to perform stress imaging of myocardial strain within a single cardiac magnetic resonance (CMR) imaging session.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse events were monitored and recorded on a specific Adverse Event (AE) log.</description>
          <population>Count of Adverse Events not clinically expect and reportable to IRB.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No Adverse Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adverse Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Serious Adverse Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Gadolinium Enhancement and CIRCUMFERENTIAL Myocardial Strain</title>
        <description>The Effects of the presence of LGE on CIRCUMFERENTIAL myocardial Strain</description>
        <time_frame>Day 1</time_frame>
        <population>LGE as determined by CMR imaging using the AHA 16 segment model.</population>
        <group_list>
          <group group_id="O1">
            <title>CONTROL</title>
            <description>A myocardial segment from an individual from a low-likelihood CAD population exhibiting both normal perfusion and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O2">
            <title>LGE-</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting normal perfusion scores and normal wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
          <group group_id="O3">
            <title>LGE+</title>
            <description>A myocardial segment from an individual from a population with CAD exhibiting a change in perfusion scores and a change in wall motion scores (rest-to-stress) on a prior clinically indicated PET.</description>
          </group>
        </group_list>
        <measure>
          <title>Late Gadolinium Enhancement and CIRCUMFERENTIAL Myocardial Strain</title>
          <description>The Effects of the presence of LGE on CIRCUMFERENTIAL myocardial Strain</description>
          <population>LGE as determined by CMR imaging using the AHA 16 segment model.</population>
          <units>strain (unitless)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Myocardial Segments</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Myocardial Segments</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.181" spread="0.057"/>
                    <measurement group_id="O2" value="-0.139" spread="0.052"/>
                    <measurement group_id="O3" value="-0.101" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REGADENOSON STRESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.169" spread="0.059"/>
                    <measurement group_id="O2" value="-0.150" spread="0.052"/>
                    <measurement group_id="O3" value="-0.111" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REST-to-STRESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.066"/>
                    <measurement group_id="O2" value="-0.011" spread="0.046"/>
                    <measurement group_id="O3" value="-0.010" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>REST vs STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>paired, t-test</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST vs STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>paired, t-test</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST vs STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.428</p_value>
            <method>paired, t-test</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.000</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.000</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.000</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regadenoson STRESS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REST-to-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.000</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-to-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>REST-to-STRESS Change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.957</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>non adjusted</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Regadenoson</title>
          <description>Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
Regadenoson: Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
Strain imaging was performed on ALL subjects in the same order with resting strain preceding regadenoson stress strain. Myocardial segments were classified based on prior clinical positron-emission-tomography (PET) results so that segmental strain response to regadenoson could be observed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal: ache/discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Numbness: Jaw/shoulder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Reported strain is not adjusted for myocardial mass.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph Soltys, PhD</name_or_title>
      <organization>Cardiovascular Imaging Technologies, LLC</organization>
      <phone>816-531-2842 ext 103</phone>
      <email>jsoltys@cvit.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

